GlassScriptPhysician profile
John M Williamson
NPI 1740847946
$50,965.66
in general payments reported to CMS, 2019-2025
12 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.45 · 2022: $350 · 2023: $27K · 2024: $13K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Consulting Fee: $5,375 · Food and Beverage: $3,859 · Travel and Lodging: $2,482 · Education: $71.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,775.00 |
| Consulting Fee | $5,375.00 |
| Food and Beverage | $3,859.23 |
| Travel and Lodging | $2,482.15 |
| Education | $71.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $41,692.46 | 2022-2025 | |
| Axsome Therapeutics, INC. | $7,451.13 | 2023-2024 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $646.17 | 2022-2025 | Caplyta |
| Alkermes, INC. | $529.67 | 2021-2024 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $243.41 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Indivior INC. | $132.31 | 2022-2024 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $121.03 | 2025 | Cobenfy |
| Hikma Pharmaceuticals USA | $63.00 | 2022 | |
| Lundbeck LLC | $42.81 | 2023 | Rexulti |
| Braeburn INC. | $15.73 | 2023 | Brixadi |
| Tris Pharma INC | $14.17 | 2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $13.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.